Cannabis
Syqe Medical Receives Regulatory Approval to Release World’s First Drug Delivery Device for Precise Dosing of Cannabis
Syqe Medical, a leading pharma-tech company, today announced the launch of the world’s first pharmaceutical-grade metered-dose cannabis inhaler in Israel, empowering physicians to prescribe precise dosages meeting pharmaceutical standards. The debut of this drug delivery device reflects Syqe’s mission to transform medical cannabis into a mainstream medical treatment.
This benchmark news is the culmination of eight years of research and development – including rigorous testing through multiple clinical trials – including four years of paving a novel regulatory path. The Syqe Inhaler and supporting clinical research is poised to unlock the global medical cannabis market by eliminating uncertainty surrounding dosage administration and alleviating physician concerns with regards to adverse events and psychoactivity. In turn, this will enable greater physician adoption of medical cannabis. Syqe’s breakthrough drug delivery technology introduces complex respiration technique automation, electronic selective dosing and remote clinical monitoring and dose control, significantly expanding the applicability of this platform well beyond cannabis.
“80% of cannabis patients inhale the plant. For too long, physicians who wish to treat these patients have been without the most basic clinical knowledge on dosing, efficacy and adverse events of cannabis,” says Perry Davidson, CEO and Founder of Syqe Medical. “For eight years Syqe has been developing proprietary technologies for the administration of raw plants, and through our clinical trials we were able to determine the recommended dosage of inhaled cannabis down to the microgram. This launch marks the beginning of a new chapter in pain treatment, one in which physicians can confidently prescribe precise dosages of cannabis, and patients can reap the rewards, effectively and responsibly.”
The Syqe Inhaler, a non-combustion drug delivery device, has received the world’s first ever regulatory approval from the Israeli Ministry of Health as a medical device combined with cannabis, and will be available for purchase by licensed patients in Israel.
The devices will be marketed and distributed by Teva Israel. The cannabis in the Syqe inhaler is produced under controlled pharmaceutical conditions, complying with good manufacturing practices (GMP).
SOURCE Syqe Medical
-
Cannabis2 weeks ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis7 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis7 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
SCHWAZZE4 days ago
Schwazze Announces First Quarter 2024 Financial Results
-
Cannabis4 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis6 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth